Literature DB >> 30455362

Serum paraoxonase 1 activity is paradoxically maintained in nonalcoholic fatty liver disease despite low HDL cholesterol.

Eline H van den Berg1,2, Eke G Gruppen1,3, Richard W James3, Stephan J L Bakker3, Robin P F Dullaart4.   

Abstract

Nonalcoholic fatty liver disease (NAFLD) is characterized by low HDL cholesterol, but the activity of the HDL-associated antioxidative enzyme paraoxonase-1 (PON-1) remains unclear. To determine the association of PON-1 with suspected NAFLD, we measured serum enzyme activity in 7,622 participants of the Prevention of Renal and Vascular End-Stage Disease cohort. A fatty liver index (FLI) ≥60, a proxy of NAFLD, was present in 2,083 participants (27.3%) and coincided with increased prevalence of T2D, metabolic syndrome (MetS), (central) obesity, elevated triglycerides, and low HDL cholesterol (all P < 0.001). In men and women combined, serum PON-1 activity did not vary according to elevated FLI (P = 0.98), whereas in men with elevated FLI PON-1 activity was increased (P = 0.016). In multivariable linear regression analyses (adjusted for age, sex, T2D, MetS, alcohol use, and smoking), PON-1 activity was unexpectedly associated with elevated FLI (β = 0.083; P < 0.001). In a sensitivity analysis (n = 5,126) that excluded subjects with positive cardiovascular history, impaired estimated glomerular filtration rate, elevated urinary albumin excretion, and drug use, PON-1 activity was also independently associated with elevated FLI (β = 0.045; P = 0.017). These results indicate that PON-1 is paradoxically maintained and may even be increased in NAFLD despite inverse associations with metabolic disorders and low HDL cholesterol.
Copyright © 2019 van den Berg et al.

Entities:  

Keywords:  fatty liver index; hepatic steatosis index; high density lipoprotein cholesterol; metabolic syndrome; nonalcoholic fatty liver disease; paraoxonase-1; type 2 diabetes mellitus

Mesh:

Substances:

Year:  2018        PMID: 30455362      PMCID: PMC6314263          DOI: 10.1194/jlr.P088997

Source DB:  PubMed          Journal:  J Lipid Res        ISSN: 0022-2275            Impact factor:   5.922


  48 in total

1.  Serum paraoxonase-1 activity is more closely related to HDL particle concentration and large HDL particles than to HDL cholesterol in Type 2 diabetic and non-diabetic subjects.

Authors:  Robin P F Dullaart; James D Otvos; Richard W James
Journal:  Clin Biochem       Date:  2014-04-21       Impact factor: 3.281

2.  The positive relationship of serum paraoxonase-1 activity with apolipoprotein E is abrogated in metabolic syndrome.

Authors:  Robin P F Dullaart; Arjan J Kwakernaak; Geesje M Dallinga-Thie
Journal:  Atherosclerosis       Date:  2013-07-01       Impact factor: 5.162

3.  Paraoxonase-1 activity, malondialdehyde and glutathione peroxidase in non-alcoholic fatty liver disease and the effect of atorvastatin.

Authors:  Waleed Samy; Mohammed A Hassanian
Journal:  Arab J Gastroenterol       Date:  2011-05-18       Impact factor: 2.076

Review 4.  Human paraoxonase-1 (PON1): Gene structure and expression, promiscuous activities and multiple physiological roles.

Authors:  Mike Mackness; Bharti Mackness
Journal:  Gene       Date:  2015-05-09       Impact factor: 3.688

5.  Estimating glomerular filtration rate from serum creatinine and cystatin C.

Authors:  Lesley A Inker; Christopher H Schmid; Hocine Tighiouart; John H Eckfeldt; Harold I Feldman; Tom Greene; John W Kusek; Jane Manzi; Frederick Van Lente; Yaping Lucy Zhang; Josef Coresh; Andrew S Levey
Journal:  N Engl J Med       Date:  2012-07-05       Impact factor: 91.245

6.  High prevalence of apolipoprotein B dyslipoproteinemias in non-alcoholic fatty liver disease: The lifelines cohort study.

Authors:  Karlijn J Nass; Eline H van den Berg; Klaas Nico Faber; Tim C M A Schreuder; Hans Blokzijl; Robin P F Dullaart
Journal:  Metabolism       Date:  2017-04-13       Impact factor: 8.694

7.  IFCC primary reference procedures for the measurement of catalytic activity concentrations of enzymes at 37 degrees C. International Federation of Clinical Chemistry and Laboratory Medicine. Part 4. Reference procedure for the measurement of catalytic concentration of alanine aminotransferase.

Authors:  Gerhard Schumann; Roberto Bonora; Ferruccio Ceriotti; Georges Férard; Carlo A Ferrero; Paul F H Franck; F Javier Gella; Wieland Hoelzel; Poul Jørgen Jørgensen; Takashi Kanno; Art Kessner; Rainer Klauke; Nina Kristiansen; Jean-Marc Lessinger; Thomas P J Linsinger; Hideo Misaki; Mauro Panteghini; Jean Pauwels; Françoise Schiele; Heinz G Schimmel; Gerhard Weidemann; Lothar Siekmann
Journal:  Clin Chem Lab Med       Date:  2002-07       Impact factor: 3.694

8.  Characterization of cDNA clones encoding rabbit and human serum paraoxonase: the mature protein retains its signal sequence.

Authors:  C Hassett; R J Richter; R Humbert; C Chapline; J W Crabb; C J Omiecinski; C E Furlong
Journal:  Biochemistry       Date:  1991-10-22       Impact factor: 3.162

9.  Involvement of xanthine oxidase and paraoxonase 1 in the process of oxidative stress in nonalcoholic fatty liver disease.

Authors:  Bing Wang; Rui-Ning Yang; Yue-Rong Zhu; Ji-Cheng Xing; Xiao-Wei Lou; Yu-Jie He; Qi-Long Ding; Ming-Yue Zhang; Hong Qiu
Journal:  Mol Med Rep       Date:  2016-12-12       Impact factor: 2.952

10.  Prevalence and determinants of non-alcoholic fatty liver disease in lifelines: A large Dutch population cohort.

Authors:  Eline H van den Berg; Marzyeh Amini; Tim C M A Schreuder; Robin P F Dullaart; Klaas Nico Faber; Behrooz Z Alizadeh; Hans Blokzijl
Journal:  PLoS One       Date:  2017-02-02       Impact factor: 3.240

View more
  8 in total

Review 1.  Paraoxonase-1 as a Regulator of Glucose and Lipid Homeostasis: Impact on the Onset and Progression of Metabolic Disorders.

Authors:  Maria João Meneses; Regina Silvestre; Inês Sousa-Lima; Maria Paula Macedo
Journal:  Int J Mol Sci       Date:  2019-08-19       Impact factor: 5.923

2.  Low Serum Paraoxonase-1 Activity Associates with Incident Cardiovascular Disease Risk in Subjects with Concurrently High Levels of High-Density Lipoprotein Cholesterol and C-Reactive Protein.

Authors:  James P Corsetti; Charles E Sparks; Richard W James; Stephan J L Bakker; Robin P F Dullaart
Journal:  J Clin Med       Date:  2019-09-01       Impact factor: 4.241

3.  Paraoxonase-1 Serum Concentration and PON1 Gene Polymorphisms: Relationship with Non-Alcoholic Fatty Liver Disease.

Authors:  Mircea Vasile Milaciu; Ștefan Cristian Vesa; Ioana Corina Bocșan; Lorena Ciumărnean; Dorel Sâmpelean; Vasile Negrean; Raluca Maria Pop; Daniela Maria Matei; Sergiu Pașca; Andreea Liana Răchișan; Anca Dana Buzoianu; Monica Acalovschi
Journal:  J Clin Med       Date:  2019-12-13       Impact factor: 4.241

4.  Higher Sodium Intake Assessed by 24 Hour Urinary Sodium Excretion Is Associated with Non-Alcoholic Fatty Liver Disease: The PREVEND Cohort Study.

Authors:  Eline H van den Berg; Eke G Gruppen; Hans Blokzijl; Stephan J L Bakker; Robin P F Dullaart
Journal:  J Clin Med       Date:  2019-12-06       Impact factor: 4.241

5.  Paraoxonase 1 and Non-Alcoholic Fatty Liver Disease: A Meta-Analysis.

Authors:  Kazuhiko Kotani; Jun Watanabe; Kouichi Miura; Alejandro Gugliucci
Journal:  Molecules       Date:  2021-04-16       Impact factor: 4.411

6.  Plasma ApoE elevations are associated with NAFLD: The PREVEND Study.

Authors:  Eline H van den Berg; James P Corsetti; Stephan J L Bakker; Robin P F Dullaart
Journal:  PLoS One       Date:  2019-08-06       Impact factor: 3.240

7.  Interactions of Paraoxonase-1 with Pharmacologically Relevant Carbamates.

Authors:  Anita Bosak; Aljoša Bavec; Tilen Konte; Goran Šinko; Zrinka Kovarik; Marko Goličnik
Journal:  Molecules       Date:  2020-01-04       Impact factor: 4.411

Review 8.  Metabolic-associated fatty liver disease and lipoprotein metabolism.

Authors:  Joerg Heeren; Ludger Scheja
Journal:  Mol Metab       Date:  2021-04-20       Impact factor: 7.422

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.